[go: up one dir, main page]

EA200300183A1 - NEW COMBINATION OF THE AGONIST (5-TH2) AND THE ANTAGONIST (5-HT6) SEROTONIN AS A PHARMACEUTICAL COMPOSITION - Google Patents

NEW COMBINATION OF THE AGONIST (5-TH2) AND THE ANTAGONIST (5-HT6) SEROTONIN AS A PHARMACEUTICAL COMPOSITION

Info

Publication number
EA200300183A1
EA200300183A1 EA200300183A EA200300183A EA200300183A1 EA 200300183 A1 EA200300183 A1 EA 200300183A1 EA 200300183 A EA200300183 A EA 200300183A EA 200300183 A EA200300183 A EA 200300183A EA 200300183 A1 EA200300183 A1 EA 200300183A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
antagonist
pharmaceutical composition
agonist
serotonin
Prior art date
Application number
EA200300183A
Other languages
Russian (ru)
Other versions
EA006604B1 (en
Inventor
Сукхвиндер Джоссан
Бьерн М. Нильссон
Хьелль С. Сакариассен
Ян Свартенгрен
Original Assignee
Биовитрум Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биовитрум Аб filed Critical Биовитрум Аб
Publication of EA200300183A1 publication Critical patent/EA200300183A1/en
Publication of EA006604B1 publication Critical patent/EA006604B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение относится к способу предупреждения или лечения болезни, связанной с рецептором 5-HTи рецептором 5-HT, включающему введение человеку или животному, нуждающемуся в этом, агониста рецептора 5-HTи антагониста рецептора 5-HTв количестве, достаточном для получения терапевтического действия. Изобретение также относится к фармацевтической композиции, содержащей эффективное количество сочетания агониста рецептора 5-HTи антагониста рецептора 5-HTи, необязательно, фармацевтически приемлемый носитель.Международная заявка была опубликована вместе с отчетом о международном поиске.The invention relates to a method of preventing or treating a disease associated with a 5-HT receptor and a 5-HT receptor, comprising administering to a person or an animal in need thereof a 5-HT receptor agonist and an antagonist of 5-HT receptor in an amount sufficient to produce a therapeutic effect. The invention also relates to a pharmaceutical composition comprising an effective amount of a 5-HT receptor agonist combination and a 5-HT receptor antagonist, optionally a pharmaceutically acceptable carrier. The international application was published together with an international search report.

EA200300183A 2000-07-21 2001-07-19 Combination of serotonin agonist (5-ht) and antagonist (5-ht) as pharmaceutical formulation EA006604B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (en) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (2)

Publication Number Publication Date
EA200300183A1 true EA200300183A1 (en) 2003-08-28
EA006604B1 EA006604B1 (en) 2006-02-24

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300183A EA006604B1 (en) 2000-07-21 2001-07-19 Combination of serotonin agonist (5-ht) and antagonist (5-ht) as pharmaceutical formulation

Country Status (18)

Country Link
EP (1) EP1301476A1 (en)
JP (1) JP2004504376A (en)
KR (1) KR100845450B1 (en)
CN (1) CN1221254C (en)
AU (2) AU8273401A (en)
BR (1) BR0112661A (en)
CA (1) CA2411192A1 (en)
EA (1) EA006604B1 (en)
HU (1) HUP0301346A3 (en)
IL (1) IL154057A0 (en)
MX (1) MXPA03000548A (en)
NO (1) NO20030304L (en)
NZ (1) NZ523216A (en)
PL (1) PL360309A1 (en)
SE (1) SE0002754D0 (en)
WO (1) WO2002008178A1 (en)
YU (1) YU2603A (en)
ZA (1) ZA200210234B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213134B1 (en) * 2000-11-02 2013-01-31 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
KR20040010709A (en) * 2001-06-15 2004-01-31 에프. 호프만-라 로슈 아게 4-piperazinylindole derivatives with 5-ht6 receptor affinity
CN1321110C (en) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 4-Piperazinoindole Derivatives with 5-HT6 Receptor Affinity
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
NZ535239A (en) 2002-03-27 2008-03-28 Glaxo Group Ltd Quinoline derivatives and their use as 5-HT6 ligands
CL2004000826A1 (en) * 2003-04-25 2005-03-04 Pfizer USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
WO2005012254A1 (en) 2003-07-22 2005-02-10 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
DE602007012080D1 (en) * 2007-08-01 2011-03-03 Esteve Labor Dr Combination of at least two 5-HT6 ligands
WO2009063992A1 (en) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Condensed pyridine derivative and use thereof
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
US9115139B2 (en) 2009-06-15 2015-08-25 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc Therapeutic agent for fibromyalgia
EP3307260A4 (en) 2015-06-12 2019-02-13 Axovant Sciences GmbH DIARYL AND ARYLHETERARYLUM DERIVATIVES USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF SLEEP BEHAVIOR DISORDER
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN107628981B (en) * 2017-10-31 2019-07-30 威海市妇女儿童医院 A kind of cinnamoyl sulfonylindoline compounds and its application for preparing glaucoma medicine
JPWO2019131902A1 (en) 2017-12-27 2020-12-10 武田薬品工業株式会社 Remedies for stress urinary incontinence and fecal incontinence
CN111269165A (en) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 Synthetic method of 3-arylsulfonyl indole derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
WO2002008178A1 (en) 2002-01-31
PL360309A1 (en) 2004-09-06
IL154057A0 (en) 2003-07-31
CA2411192A1 (en) 2002-01-31
EA006604B1 (en) 2006-02-24
NZ523216A (en) 2005-05-27
HUP0301346A2 (en) 2003-08-28
EP1301476A1 (en) 2003-04-16
KR100845450B1 (en) 2008-07-10
AU8273401A (en) 2002-02-05
KR20030036599A (en) 2003-05-09
MXPA03000548A (en) 2004-04-05
CN1221254C (en) 2005-10-05
BR0112661A (en) 2003-06-24
ZA200210234B (en) 2004-03-18
AU2001282734B2 (en) 2006-10-12
CN1443162A (en) 2003-09-17
NO20030304D0 (en) 2003-01-20
NO20030304L (en) 2003-03-12
SE0002754D0 (en) 2000-07-21
HUP0301346A3 (en) 2005-05-30
HK1057536A1 (en) 2004-04-08
YU2603A (en) 2006-05-25
JP2004504376A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
EA200300183A1 (en) NEW COMBINATION OF THE AGONIST (5-TH2) AND THE ANTAGONIST (5-HT6) SEROTONIN AS A PHARMACEUTICAL COMPOSITION
EA200100284A1 (en) 5HT1 AGONISTS OF RECEPTORS AND METHOCLOPRAMID FOR THE TREATMENT OF MIGRAINE
EA200101156A1 (en) DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC
EA200400589A1 (en) HIGH-SELECTIVE INHIBITORS OF REVERSE CAPTURE OF NOREPINEFRIN AND METHODS OF THEIR APPLICATION
BRPI0409128A (en) use of peripheral opioid antagonists, especially methylnaltrexone to treat irritable bowel syndrome
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
EA200100748A1 (en) MONOAMINE RETURN INHIBITORS FOR THE TREATMENT OF CNS DISORDERS
EA200300527A1 (en) NEW TREATMENT METHODS FOR TIRED FOOT SYNDROME
DE69925024D1 (en) USE OF EPH RECEPTOR ANTAGONISTS AND AGONISTS FOR THE TREATMENT OF VASCULAR DISEASES
DK1265630T3 (en) Use of insulin for the treatment of cartilage disease
TR200002786T2 (en) A new galenic formulation for meloxicam.
BG66085B1 (en) Phenylalanine derivatives
EA200300441A1 (en) ASSOCIATION OF THE ANTAGONIST OF THE RECEPTOR CB1 AND SIBUTRAMINE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION FOR THE TREATMENT OF OBESITY
EA200100780A1 (en) TWEAK ANTAGONISTS AND TWEAK RECEPTORS AND THEIR USE FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES
EA200401584A1 (en) METHOD OF ASSISTANCE TO STOP SMOKING
EA200200132A1 (en) SELECTIVE ANTAGONISTS OF THE RECEPTOR iGluRD FOR THE TREATMENT OF MIGRAINE
MXPA05008838A (en) Rapid absorption selective 5-ht agonist formulations.
EA200300503A1 (en) NEW MEDICINAL COMPOSITIONS BASED ON SALTS OF TIOTROPY AND SALTS OF SALMETEROL
CY1118924T1 (en) METHOD FOR THE TREATMENT OF FIRST AUTOPATH
SE9900961D0 (en) Novel compounds
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
IS6558A (en) Mixed disease treatment with vasoconstrictor
SE9802208D0 (en) Novel compounds
CO5190664A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA ADMINISTRATION OF A 5HT RECEPTOR, CAFFEINE AND A CYCLLOXYGENASA-2 INHIBITOR
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU